Drug intelligence / Profile preview

NV-07a

Development stage: Unknown
Lead developer: Kazia Therapeutics
Modality: Small Molecules
Administration: Topical, Oral, Rectal

Overview

NV-07a is a synthetic phenolic small molecule developed by Novogen Ltd. for topical application. It functions as an immune modulator designed to protect the skin from sun-induced immunosuppression and ultraviolet (UV)-induced damage. By targeting immune cells in the skin, NV-07a aims to reverse immediate effects of sunlight, such as erythema (reddening), and mitigate underlying damage that can lead to skin cancer. The compound has been evaluated in Phase I clinical trials involving nickel-sensitive and mantoux-positive patients to assess its immunomodulatory effects and safety profile.

Beyond the preview

Go deeper on NV-07a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-07a.

Explore the full profile